Clinical Trials
8 trialsNCT04584255 2026-05-13
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT05601440 2026-05-07
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT01042379 2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2 Recruiting
NCT05169437 2025-10-29
PAVO
Tempus AI
Phase 2 Terminated
NCT04837209 2025-10-01
NADiR
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT04641247 2025-09-29
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study
GlaxoSmithKline
Phase 2 Recruiting
NCT04240106 2024-02-16
LUZERN
MedSIR
Phase 2 Completed
NCT02826512 2022-07-18
A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
The Netherlands Cancer Institute
Phase 2 Terminated